End-stage kidney disease

This early study tests a new medicine called TNX-1500 in 5 people who get a kidney transplant. The goal is to see if it is safe and can help prevent the body from rejecting the new kidney. Participants will be followed for one year to check for side effects and signs of rejection…

This trial tests whether tocilizumab, an anti-inflammatory drug, can stop the progression of calciphylaxis—a rare condition where calcium buildup blocks skin blood vessels, causing painful, non-healing wounds. Ten adults with calciphylaxis and end-stage kidney disease will receiv…

This study tests whether taking a short course of the drug sirolimus (Rapamycin) can improve how well older adults on hemodialysis respond to flu and RSV vaccines. Sixty participants will receive the vaccines plus sirolimus at different times. The goal is to see if this approach …

Researchers at Assiut University Hospitals compare adults with kidney failure who receive hemodialysis twice a week versus three times a week. The study tracks health-related quality of life, dialysis adequacy, urine output, and hospitalizations over time. About 130 participants …

This study looks at two ways to prevent blood clots during dialysis in people with end-stage kidney disease. Twenty adults will try both methods—one using standard heparin and the other using a citrate-based approach—to see which causes less inflammation and removes waste better.…

This pilot study will test whether a potassium-containing salt substitute is safe for people with end-stage kidney disease on hemodialysis. Twenty participants will use the salt substitute for 16 days and regular table salt for 16 days, with a break in between. Researchers will m…